Eric Lefkofsky, CEO and founder of Tempus AI, explains to Scottish Mortgage manager Tom Slater the huge potential in personalising cancer diagnosis and treatment at scale. Capital at risk.

Tempus AI (NASDAQ: TEM) is utilizing artificial intelligence to deliver better healthcare outcomes. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was up 12.7% on Wednesday after Needham & Company LLC raised their price target on the stock from $56.00 to $70.00. Needham & Company LLC currently has a ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

In a regulatory filing, Tempus AI (TEM) disclosed that its CEO Eric Lefkofsky disposed of 3.24M shares of company stock in a series of ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Tempus AI (NASDAQ:TEM – Get Free Report) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Cathie Wood and Ark Invest moved to acquire Transfus AI (TEM, Financial) shares after its share price dropped by 1.5%. Wood's ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen ...